Cancer pill may boost ablation success in aggressive liver tumors

NCT ID NCT05113186

Ongoing Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the targeted drug lenvatinib, given before and after a standard tumor-burning procedure (ablation), can help prevent liver cancer from returning in patients with aggressive tumors. About 32 adults with high-risk features (like high AFP levels or infiltrative tumors) will receive lenvatinib for 21 days before ablation and for 3 months after. The main goal is to see if this combination improves local recurrence-free survival at one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lenvatinib (a targeted cancer pill)
What this could lead to: If it works, this could point toward a way to lower the chance of liver cancer coming back after ablation in patients with aggressive tumors.
What could go wrong: This is a very small, early-phase trial with only 32 participants. It may not show a clear benefit, and lenvatinib can cause side effects like high blood pressure, fatigue, and liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

NAHON

Bobigny, 93000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.